In order to address the issue of therapeutic resistance driven by reprogramming of tumor glutamine metabolism, future studies must thoroughly examine the heterogeneity of glutamine dependence in different genetic backgrounds (e.g., KRAS-mutant vs. EGFR-mutant tumors) and further elucidate the dynamic metabolic features of drug-resistant cells. Here, EGFR is linked to neoplasm.